Novavax : Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development

May 22, 2008 - Novavax, Inc. (Nasdaq: NVAX) announced that it has created a new proprietary process to develop a vaccine candidate against Severe Acute Respiratory Syndrome (SARS). The company also received renewed research funding from the National Institutes of Health (NIH) to continue preclinical development of SARS vaccine candidates using Novavax's virus-like particle (VLP) technology... [PDF] Novavax's Press Release -